Beckman Coulter Diagnostics Earns CE Mark for New Assay Delivering Bacterial vs. Viral Infection Results in Approximately 20 Minutes

Modeling Shows Adoption of New Access MeMed BV Assay Could Cut up to €80M in Avoidable Costs across European Health Systems through Fewer Unnecessary Admissions and Testing  BREA, Calif., April 13, 2026 /PRNewswire/ -- Beckman Coulter Diagnostics, a Danaher company and global leader in clinical diagnostics, today announced it has received CE 2797 mark under IVDR for the Access MeMed BV assay, enabling broad availability of a high-throughput host‑response test that helps clinicians differentiate between bacterial and viral infections in approximately 20 minutes.